Top of the morning to you, and a fine one it is here in Boston, where we are close to wrapping our latest trip to the corporate offices. We look forward to returning to the Pharmalot campus, of course, but meanwhile, we are as busy as ever foraging for interesting items. The task is made easier, though, thanks to some cups of stimulation. No surprise, right? As always, here are some tidbits. Have a successful day and do keep in touch …
Allergan is beginning an aggressive sales campaign for Kybella, the first injectable treatment for what doctors call “submental fat” in your jowls, Bloomberg News says. The drug maker, which spent $2.1 billion last year to acquire the treatment, plans to start the advertising blitz in September. The treatment involves up to 30 tiny injections that must avoid nerves and blood vessels running under the jawline.
A shareholder advisory firm says AstraZeneca shareholders should oppose the pay package for chief executive officer Pascal Soriot because his compensation is excessive and bonus targets were not disclosed, Bloomberg News tells us. His bonus and long-term incentives were 580 percent of his salary, according to Pensions & Investment Research Consultants. His annual bonus was not disclosed because it is considered commercially sensitive information.
Who would want to probably pay more for six treatments with Kybella and all of the side effects when a single 30 minute submental liposuction would achieve a better, faster and less painful result.
Concerning the Tysbari patent challenge – would they that make them Swiss Pharma patent trolls … or ”patent tyrolls?’ So to speak ….
Comments are closed.